South Rampart Pharma
Clinical-stage biopharmaceutical company developing non-opioid, non-NSAID small-molecule analgesics designed to provide analgesia without hepatotoxicity, nephrotoxicity, or abuse potential. The company advances candidates through preclinical, IND-enabling and clinical development (Phase 1 completed; Phase 2 planned), supports CMC and regulatory activities, and publishes mechanistic and safety data in peer-reviewed journals.
Industries
Nr. of Employees
small (1-50)
South Rampart Pharma
Patents
Products
SRP-001 (investigational small-molecule analgesic)
First-in-class investigational non-opioid, non-NSAID small molecule designed to provide central analgesia via formation of an active metabolite in the midbrain while avoiding hepatotoxic and nephrotoxic pathways; completed Phase 1 trial with safety, tolerability, and favorable pharmacokinetics and being advanced into Phase 2 randomized clinical trials for acute and neuropathic pain. Multiple formulations under development (oral, IV, topical).
SRP-001
SRP-001 is a non-opioid analgesic that has completed phase 1 study and is currently advancing toward a Phase 2 randomized, double-blind, placebo-controlled clinical trial in acute pain.
SRP-3D (DA)
A novel non-opioid small molecule supported by South Rampart Pharma, Inc. for clinical pharmacology and toxicology development.
SRP-001 (investigational small-molecule analgesic)
First-in-class investigational non-opioid, non-NSAID small molecule designed to provide central analgesia via formation of an active metabolite in the midbrain while avoiding hepatotoxic and nephrotoxic pathways; completed Phase 1 trial with safety, tolerability, and favorable pharmacokinetics and being advanced into Phase 2 randomized clinical trials for acute and neuropathic pain. Multiple formulations under development (oral, IV, topical).
SRP-001
SRP-001 is a non-opioid analgesic that has completed phase 1 study and is currently advancing toward a Phase 2 randomized, double-blind, placebo-controlled clinical trial in acute pain.
SRP-3D (DA)
A novel non-opioid small molecule supported by South Rampart Pharma, Inc. for clinical pharmacology and toxicology development.
Expertise Areas
- Non-opioid analgesic discovery
- Preclinical pharmacology and toxicology
- CMC and process development for small molecules
- Early-phase clinical trial management
Key Technologies
- Single-cell RNA sequencing
- ATAC sequencing (chromatin accessibility)
- Spatial transcriptomics
- LC-MS/MS metabolomics
News & Updates
U.S. FDA granted Fast Track designation for the company's lead investigational analgesic for acute pain.
Completed Phase 1 clinical trial demonstrating safety, tolerability, and robust pharmacokinetics; announced expansion of Phase 2 plans to include neuropathic and acute pain trials.
Peer-reviewed publication reporting single-cell transcriptomics, mechanism-of-action via AM404 formation in the midbrain PAG, safety (non-hepatotoxic), and PK results from a Phase 1 trial.
Published study describing genomic and epigenomic effects in the PAG midbrain region and mechanistic data supporting non-toxic central analgesia.
Awarded $1.9M NIH STTR Fast-Track grant to support preclinical and early clinical development; advanced to Phase II portion of the award.
Announced expansion of composition-of-matter and related patents across multiple jurisdictions including EU, China, India, Japan and others.
U.S. FDA granted Fast Track designation for the company's lead investigational analgesic for acute pain.
Completed Phase 1 clinical trial demonstrating safety, tolerability, and robust pharmacokinetics; announced expansion of Phase 2 plans to include neuropathic and acute pain trials.
Peer-reviewed publication reporting single-cell transcriptomics, mechanism-of-action via AM404 formation in the midbrain PAG, safety (non-hepatotoxic), and PK results from a Phase 1 trial.
Published study describing genomic and epigenomic effects in the PAG midbrain region and mechanistic data supporting non-toxic central analgesia.
Awarded $1.9M NIH STTR Fast-Track grant to support preclinical and early clinical development; advanced to Phase II portion of the award.
Announced expansion of composition-of-matter and related patents across multiple jurisdictions including EU, China, India, Japan and others.